Skip to content

Released Aug 6, 2021, after the close

10-Q filed Aug 9, 2021, 40 days after period end · 0001564590-21-042217

Q2 2021 · 10-Q
Revenue$28.05M+196.2% vs Q2 2020+91.3% vs Q1 2021
Net Income-$6.15MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.13N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$9,805,000N/M
Operating Cash Flowderived-$5,263,000N/M
Margins · derived
Operating margin-35.0%+138.4 pt vs Q2 2020
Net margin-21.9%

What the release said

The release

Same quarter

MetricQ2 2021Q2 2020Q2 2019Q2 2018
Revenue$28.05M$9.47M$10.53M$5.70M
Net Income-$6.15M$29.87M-$13.79M-$11.54M
EPS Diluted-$0.13$0.94-$0.60-$24.17

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR